Targeting GGTase-I activates RHOA, increases macrophage reverse cholesterol transport, and reduces atherosclerosis in mice

Circulation

Volumn 127, Issue 7, 2013, Pages 782-790

  Khan, Omar M ^a   Akula, Murali K ^a   Skålen, Kristina ^a   Karlsson, Christin ^a   Ståhlman, Marcus ^a   Young, Stephen G ^b   Borén, Jan ^a   Bergo, Martin O ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

atherosclerosis; cholesterol; hydroxymethylglutaryl CoA reductase inhibitors; macrophages; prenylation; statins

Indexed keywords

CHOLESTEROL ESTER; CYCLOOXYGENASE 2; GERANYLGERANYLTRANSFERASE 1; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOLIPID; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DISEASE COURSE; ENZYME INACTIVATION; INFLAMMATION; LIPID BLOOD LEVEL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; UPREGULATION;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTIGENS, CD36; AORTA; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; BONE MARROW CELLS; CELL LINE, TUMOR; CHOLESTEROL; CYCLOOXYGENASE 2; FEMALE; FOAM CELLS; HUMANS; LEUKEMIA, MONOCYTIC, ACUTE; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, KNOCKOUT; PPAR GAMMA; RHO GTP-BINDING PROTEINS; SCAVENGER RECEPTORS, CLASS B; SIGNAL TRANSDUCTION; VASCULITIS;

EID: 84874117435     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.000588     Document Type: Article

References (56)

1. Zhang FL, Casey PJ. Influence of metal ions on substrate binding and catalytic activity of mammalian protein geranylgeranyltransferase type-I. Biochem J. 1996;320(pt 3):925-932. (Pubitemid 27013811)
2. Hall A. G proteins and small GTPases: distant relatives keep in touch. Science. 1998;280:2074-2075. (Pubitemid 28366192)
3. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol. 2008;9:690-701.
4. Hori Y, Kikuchi A, Isomura M, Katayama M, Miura Y, Fujioka H, Kaibuchi K, Takai Y. Post-translational modifications of the C-terminal region of the rho protein are important for its interaction with membranes and the stimulatory and inhibitory GDP/GTP exchange proteins. Oncogene. 1991;6:515-522. (Pubitemid 21924114)
5. Solski PA, Helms W, Keely PJ, Su L, Der CJ. RhoA biological activity is dependent on prenylation but independent of specific isoprenoid modification. Cell Growth Differ. 2002;13:363-373.
6. Connor AM, Berger S, Narendran A, Keystone EC. Inhibition of protein geranylgeranylation induces apoptosis in synovial fibroblasts. Arthritis Res Ther. 2006;8:R94.
7. Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum. 2006;54:579-586. (Pubitemid 43228634)
8. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006;6:358-370.
9. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest. 2001;107:1423-1432. (Pubitemid 32522036)
10. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4:977-987.
11. Kumai T, Matsumoto N, Koitabashi Y, Takeba Y, Oonuma S, Sekine S, Tadokoro M, Kobayashi S. Pleiotropic effects of 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors: candidate mechanisms for antilipid deposition in blood vessels. Curr Med Chem Cardiovasc Hematol Agents. 2005;3:195-201. (Pubitemid 40974780)
12. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719. (Pubitemid 34219772)
13. Veillard NR, Braunersreuther V, Arnaud C, Burger F, Pelli G, Steffens S, Mach F. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis. 2006;188:51-58. (Pubitemid 44142533)
14. Kotamraju S, Williams CL, Willams CL, Kalyanaraman B. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res. 2007;67:7386-7394. (Pubitemid 47206569)
15. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, Liao JK. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429-1437. (Pubitemid 33091980)
16. Ostrowski SM, Wilkinson BL, Golde TE, Landreth G. Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem. 2007;282:26832-26844. (Pubitemid 47501902)
17. Khan OM, Ibrahim MX, Jonsson IM, Karlsson C, Liu M, Sjogren AK, Olofsson FJ, Brisslert M, Andersson S, Ohlsson C, Hult LM, Bokarewa M, Bergo MO. Geranylgeranyltransferase type I (GGTase-I) deficiency hyperactivates macrophages and induces erosive arthritis in mice. J Clin Invest. 2011;121:628-639.
18. Nofer JR, Remaley AT, Feuerborn R, Wolinnska I, Engel T, von Eckardstein A, Assmann G. Apolipoprotein A-I activates Cdc42 signaling through the ABCA1 transporter. J Lipid Res. 2006;47:794-803.
19. Nofer JR, Feuerborn R, Levkau B, Sokoll A, Seedorf U, Assmann G. Involvement of Cdc42 signaling in apoA-I-induced cholesterol efflux. J Biol Chem. 2003;278:53055-53062. (Pubitemid 38035908)
20. Argmann CA, Edwards JY, Sawyez CG, O'Neil CH, Hegele RA, Pickering JG, Huff MW. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition. J Biol Chem. 2005;280:22212-22221.
21. Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, Motoshima H, Taguchi T, Sonoda K, Kukidome D, Takuwa Y, Kawada T, Brownlee M, Nishikawa T, Araki E. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinasedependent cyclooxygenase-2 expression in macrophages. Circ Res. 2007;100:1442-1451. (Pubitemid 46834756)
22. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Rosuvastatin blocks advanced glycation end products-elicited reduction of macrophage cholesterol efflux by suppressing NADPH oxidase activity via inhibition of geranylgeranylation of Rac-1. Horm Metab Res. 2011;43:619-624.
23. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204-212.
24. Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol. 2011;7:399-408.
25. Gan X, Kaplan R, Menke JG, MacNaul K, Chen Y, Sparrow CP, Zhou G, Wright SD, Cai TQ. Dual mechanisms of ABCA1 regulation by geranylgeranyl pyrophosphate. J Biol Chem. 2001;276:48702-48708.
26. Sjogren AK, Andersson KM, Liu M, Cutts BA, Karlsson C, Wahlstrom AM, Dalin M, Weinbaum C, Casey PJ, Tarkowski A, Swolin B, Young SG, Bergo MO. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J Clin Invest. 2007;117:1294-1304. (Pubitemid 46718417)
27. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993;92:883-893. (Pubitemid 23262411)
28. Babaev VR, Patel MB, Semenkovich CF, Fazio S, Linton MF. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice. J Biol Chem. 2000;275:26293-26299.
29. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987;68:231-240. (Pubitemid 17159775)
30. Purcell-Huynh DA, Farese RV Jr, Johnson DF, Flynn LM, Pierotti V, Newland DL, Linton MF, Sanan DA, Young SG. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest. 1995;95:2246-2257.
31. Furuhashi M, Tuncman G, Gg CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature. 2007;447:959-965. (Pubitemid 46975747)
32. Garber DW, Kulkarni KR, Anantharamaiah GM. A sensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samples. J Lipid Res. 2000;41:1020-1026. (Pubitemid 30434334)
33. Takeshita S, Kaji K, Kudo A. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res. 2000;15:1477-1488. (Pubitemid 30484517)
34. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226:497-509.
35. Stlman M, Pham HT, Adiels M, Mitchell TW, Blanksby SJ, Fagerberg B, Ekroos K, Bor J. Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-Bcontaining lipoproteins from women with type 2 diabetes. Diabetologia. 2012;55:1156-1166.
36. Bergo MO, Gavino BJ, Hong C, Beigneux AP, McMahon M, Casey PJ, Young SG. Inactivation of Icmt inhibits transformation by oncogenic KRas and B-Raf. J Clin Invest. 2004;113:539-550. (Pubitemid 38542503)
37. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer. 1980;26:171-176. (Pubitemid 10086416)
38. Smoak KA, Aloor JJ, Madenspacher J, Merrick BA, Collins JB, Zhu X, Cavigiolio G, Oda MN, Parks JS, Fessler MB. Myeloid differentiation primary response protein 88 couples reverse cholesterol transport to inflammation. Cell Metab. 2010;11:493-502.
39. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003;108:661-663. (Pubitemid 36999247)
40. Kmerer I, Ringseis R, Biemann R, Wen G, Eder K. 13-Hydroxy linoleic acid increases expression of the cholesterol transporters ABCA1, ABCG1 and SR-BI and stimulates apoA-I-dependent cholesterol efflux in RAW264.7 macrophages. Lipids Health Dis. 2011;10:222.
41. Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, Chapman J, Fruchart JC, Tedgui A, Najib-Fruchart J, Staels B. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation. 2000;101:2411-2417. (Pubitemid 30329133)
42. Bujold K, Rhainds D, Jossart C, Febbraio M, Marleau S, Ong H. CD36-mediated cholesterol efflux is associated with PPARgamma activation via a MAPK-dependent COX-2 pathway in macrophages. Cardiovasc Res. 2009;83:457-464.
43. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874. (Pubitemid 36019640)
44. Levin MC, Jirholt P, Wramstedt A, Johansson ME, Lundberg AM, Trajkovska MG, Stlman M, Fogelstrand P, Brisslert M, Fogelstrand L, Yan ZQ, Hansson GK, Bjkbacka H, Olofsson SO, Bor J. Rip2 deficiency leads to increased atherosclerosis despite decreased inflammation. Circ Res. 2011;109:1210-1218.
45. Kanters E, Pasparakis M, Gijbels MJ, Vergouwe MN, Partouns-Hendriks I, Fijneman RJ, Clausen BE, Fster I, Kockx MM, Rajewsky K, Kraal G, Hofker MH, de Winther MP. Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2003;112:1176-1185. (Pubitemid 38056294)
46. Kanters E, Gijbels MJ, van der Made I, Vergouwe MN, Heeringa P, Kraal G, Hofker MH, de Winther MP. Hematopoietic NF-kappaB1 deficiency results in small atherosclerotic lesions with an inflammatory phenotype. Blood. 2004;103:934-940. (Pubitemid 38129553)
47. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125:1905-1919.
48. Tall AR, Costet P, Wang N. Regulation and mechanisms of macrophage cholesterol efflux. J Clin Invest. 2002;110:899-904.
49. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med. 2008;263:256-273. (Pubitemid 351207349)
50. Berrougui H, Grenier G, Loued S, Drouin G, Khalil A. A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis. 2009;207:420-427.
51. Owen JS. Role of ABC1 gene in cholesterol efflux and atheroprotection. Lancet. 1999;354:1402-1403. (Pubitemid 29494746)
52. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8:222-232.
53. Forman BM, Ruan B, Chen J, Schroepfer GJ Jr, Evans RM. The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc Natl Acad Sci USA. 1997;94:10588-10593.
54. Yang SH, Chang SY, Tu Y, Lawson GW, Bergo MO, Fong LG, Young SG. Severe hepatocellular disease in mice lacking one or both CaaX prenyltransferases. J Lipid Res. 2012;53:77-86.
55. Zipp F, Waiczies S, Aktas O, Neuhaus O, Hemmer B, Schraven B, Nitsch R, Hartung HP. Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol Sci. 2007;28:342-349. (Pubitemid 47016681)
56. Landrier JF, Thomas C, Grober J, Duez H, Percevault F, Souidi M, Linard C, Staels B, Besnard P. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptoralpha-dependent. J Biol Chem. 2004;279:45512-45518. (Pubitemid 39491537)